Navigation Links
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
Date:8/3/2009

at include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Announces Pricing of Public Offering of Common Stock
2. Micromet Announces Public Offering of Common Stock
3. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
4. Micromet Added to Russell 3000 Index
5. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
6. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
7. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
8. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
9. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
10. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
11. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Die SARAH-Studie ... Assistance Publique - Hôpitaux de ... französische, gemeinschaftliche, randomisierte Kontrollstudie für die mehr ... werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC), ... behandelt wurden. Die Ergebnisse werden für Ende ...
(Date:3/5/2015)... ARLINGTON, Va. , March 5, 2015   ... selected as semi-finalists in the HX360 Innovation Challenge ... eighty-three entries, will compete to be chosen as one ... a panel of senior health system executives and venture ... The HX360 Innovation Challenge takes place at the 2015 ...
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the hiring ... of Managed Care. In this role, Damm will build ... nation’s leading specialty pharmacies. , Damm, who is based ... pharmacy and biotech experience to his new position with ... and Pfizer. Prior to working in Healthcare Damm served ...
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... , , , MOUNTAIN ... a pharmaceutical company dedicated to the development and commercialization of novel therapeutic ... overview of the company at four healthcare investment conferences during the month ... as follows: , , , ...
... COPENHAGEN and OSLO, September 1 Affitech A/S,(Nasdaq ... that it,has appointed two experienced biotech executives to ... of Celldex Therapeutics Inc., has today,assumed overall responsibility ... Alexander Duncan, previously SVP Biopharmaceuticals for Astra,Zeneca - ...
... Funds will extend the National ... Honolulu, HI ... $2.8 million in research funding from the National Cancer Institute (NCI) to continue the National ... years. , , , , ,Since 2002, PHRI has participated in the NLST, a research ...
Cached Biology Technology:VIVUS to Present at Four Upcoming Healthcare Conferences 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) ... Global Market Overview" report to their offering. , ... ensure that an individual is who she/he is claiming to ... of a person,s unique physical characteristics, such as fingerprint, hand ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... The coal tit appears to live a strictly ... That,s only a facade. This indigenous songbird is among the ... at the University of Bonn shows. For this they have ... their young. In this way they were able to identify ...
... Va.With positron emission tomography (PET) imaging, seeing is ... non-Hodgkin lymphoma (NHL) typically involves visual interpretation of ... measuring a quantitative indexone that reflects the reduction ... information about patients responses to first-line chemotherapy, according ...
... for Halloween, researchers are releasing new data that show darkness ... for publication in the November 15th issue of Biological Psychiatry. ... anticipation and excitement of this spooky holiday, this study lends ... Grillon and colleagues at the National Institute ...
Cached Biology News:Age increases chance of success as two-timer 2Age increases chance of success as two-timer 3Quantitative PET imaging finds early determination of effectiveness of cancer treatment 2Social stress + darkness = increased anxiety 2
Anti-Src-Like Adaptor Protein-2 AVOID FREEZE/THAW CYCLES. Recognizes the ~25 and ~28 kDa forms SLAP-2....
...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
... low background ,This solution greatly enhances antigen-antibody ... than obtained with conventional methods. ,Two kinds ... secondary antibodies, which can suppress the background ... Wide versatility ,It is applicable to various ...
Biology Products: